Quadrant Capital Group LLC Has $280,000 Position in Shire PLC (SHPG)

Quadrant Capital Group LLC increased its position in shares of Shire PLC (NASDAQ:SHPG) by 3.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,839 shares of the biopharmaceutical company’s stock after acquiring an additional 66 shares during the quarter. Quadrant Capital Group LLC’s holdings in Shire PLC were worth $280,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. American International Group Inc. boosted its holdings in shares of Shire PLC by 1.2% in the 1st quarter. American International Group Inc. now owns 4,607 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 54 shares during the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of Shire PLC by 7.9% in the 1st quarter. Neuberger Berman Group LLC now owns 14,944 shares of the biopharmaceutical company’s stock valued at $2,604,000 after purchasing an additional 1,095 shares during the last quarter. United Services Automobile Association boosted its holdings in shares of Shire PLC by 4.1% in the 1st quarter. United Services Automobile Association now owns 16,225 shares of the biopharmaceutical company’s stock valued at $2,827,000 after purchasing an additional 641 shares during the last quarter. Stephens Inc. AR acquired a new position in shares of Shire PLC in the 1st quarter valued at $179,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in shares of Shire PLC in the 1st quarter valued at $3,515,000. Hedge funds and other institutional investors own 19.28% of the company’s stock.

Shire PLC (NASDAQ:SHPG) traded up 1.03% during midday trading on Tuesday, reaching $151.79. 276,756 shares of the company traded hands. Shire PLC has a 12 month low of $139.36 and a 12 month high of $194.60.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. On average, equities analysts predict that Shire PLC will post $14.93 earnings per share for the current year.

The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be issued a dividend of $0.1527 per share. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio is currently 41.07%.

TRADEMARK VIOLATION NOTICE: “Quadrant Capital Group LLC Has $280,000 Position in Shire PLC (SHPG)” was first posted by Markets Daily and is owned by of Markets Daily. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright law. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/10/10/quadrant-capital-group-llc-has-280000-position-in-shire-plc-shpg.html.

A number of equities analysts have weighed in on SHPG shares. Zacks Investment Research lowered shares of Shire PLC from a “hold” rating to a “sell” rating in a report on Monday, July 17th. BidaskClub lowered shares of Shire PLC from a “hold” rating to a “sell” rating in a report on Saturday, July 1st. ValuEngine lowered shares of Shire PLC from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Cantor Fitzgerald reiterated a “buy” rating and issued a $222.00 price target on shares of Shire PLC in a report on Thursday, September 14th. Finally, BTIG Research reiterated a “buy” rating and issued a $242.00 price target on shares of Shire PLC in a report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $220.91.

Shire PLC Profile

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply